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OBJECTIVE
To describe baseline characteristics of the Vitamin D and Type 2 Diabetes (D2d)
study, the ﬁrst large U.S. diabetes prevention clinical trial to apply current American
Diabetes Association (ADA) criteria for prediabetes.
RESEARCH DESIGN AND METHODS
This is a multicenter (n = 22 sites), randomized, double-blind, placebo-controlled,
primary prevention clinical trial testing effects of oral daily 4,000 IU cholecalciferol
(D3) compared with placebo on incident diabetes in U.S. adults at risk for diabetes.
Eligible participants were at risk for diabetes, deﬁned as not meeting criteria for
diabetes butmeeting at least two 2010 ADA glycemic criteria for prediabetes: fasting
plasma glucose (FPG) 100–125 mg/dL, 2-h postload glucose (2hPG) after a 75-g oral
glucose load 140–199 mg/dL, and/or a hemoglobin A1c (HbA1c) 5.7–6.4% (39–
46 mmol/mol).
RESULTS
A total of 2,423 participants (45% of whom were women and 33% nonwhite) were
randomized to cholecalciferol or placebo. Mean (SD) age was 59 (9.9) years and BMI
32 (4.5) kg/m2. Thirty-ﬁve percent met all three prediabetes criteria, 49% met the
FPG/HbA1c criteria only, 9.5% met the 2hPG/FPG criteria only, and 6.3% met the
2hPG/HbA1c criteria only. Black participants had the highest mean HbA1c and lowest
FPG concentration compared with white, Asian, and other races (P < 0.01); 2hPG
concentration did not differ among racial groups. When compared with previous
prediabetes cohorts, the D2d cohort had lowermean 2hPG concentration but similar
HbA1c and FPG concentrations.
CONCLUSIONS
D2d will establish whether vitamin D supplementation lowers risk of diabetes and
will inform about the natural history of prediabetes per contemporary ADA criteria.
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Prediabetes, typically deﬁned as blood
glucose concentrations above normal but
below the threshold for diabetes, is a dis-
ease risk state that predicts an increased
probability of developing diabetes and
may itself be associated with health risks
and complications (1). Although lifestyle
changes can reduce the rate of progres-
sion to diabetes, achieving as well as
maintaining sufﬁcient lifestyle change is
challenging (2). Therefore, simple, sus-
tainable, and complementary prevention
approaches are needed. The Vitamin D
and Type 2 Diabetes (D2d) study is the
largest clinical trial to examine the causal
relationship between vitamin D supple-
mentation and the development of di-
abetes in people at risk for diabetes (3).
D2d is also the largest U.S.-based study to
have assembled and followed a contem-
porary cohort of people at risk for diabetes,
deﬁned as meeting at least two prediabe-
tes criteria by the American Diabetes As-
sociation (ADA) (4).
In 2003, the ADA revised the criteria for
prediabetes to lower the threshold for
fasting plasma glucose (FPG) from 110 to
100 mg/dL (5.6 mmol/L), and in 2010,
hemoglobin A1c (HbA1c) of 5.7–6.4% (39–
46 mmol/mol) was added as a criterion
based on evidence of increased diabetes
complications at these glycemic ranges
(4). The 2-h postload glucose (2hPG) after
a 75-g oral glucose load criterion was
unchanged. The expanded criteria have
been controversial (5,6). First, the natural
history of prediabetes, based on the
ADA’s current deﬁnition, has not been
established in the modern era. Second,
most data on the natural history of pre-
diabetes are .20 years old (7–10) or
were not conducted in populations gen-
eralizable to the current U.S. population
(8–12). Third, some have argued that
lowering the FPG threshold and adding
the HbA1c criterion increase the preva-
lence of prediabetes without a clear asso-
ciation with clinically important outcomes
and may lead to an unnecessary medical-
ization of prediabetes (13,14). Finally,
there is evidence of interindividual variation
in HbA1c relative to underlying glucose
levels, with a tendency for black individuals
to have higher HbA1c compared with
whites with similar glucose levels (15).
In the current report, we describe the
baseline characteristics of the D2d pre-
diabetes cohort and compare them with
prior diabetes prevention studies that used
different enrollment criteria. As the largest
clinical trial to enroll a contemporary
cohort of American adults with prediabe-
tes, D2d will ﬁll important gaps in knowl-
edge related to the current deﬁnition of
prediabetes.
RESEARCH DESIGN AND METHODS
Overview of Study Design
D2d is a U.S.-based, multicenter, random-
ized (1:1), double-blind, placebo-controlled,
parallel-group, primary prevention clinical
trial comparing oral administration of 4,000
IU/day of cholecalciferol (vitamin D3) ver-
sus placebo in people with prediabetes
who are followed for incident diabetes
for;3 years after randomization. Cancer
and cardiovascular disease are key sec-
ondary outcomes. The design of D2d has
been published (3). The study is approved
and monitored by an independent data-
and safety-monitoring board and the
institutional review board of each col-
laborating clinical research site.
Study Population and Setting
Target participants were adults at risk for
diabetes. At the baseline visit, eligible
participants met at least two of three
glycemic criteria for prediabetes estab-
lished by the ADA in 2010 (4): FPG 100–
125mg/dL (5.6–6.9 mmol/L), or impaired
fasting glucose (IFG); 2hPG after a 75-g
glucose load 140–199 mg/dL (7.8–
11.0mmol/L), or impaired glucose tolerance
(IGT); HbA1c 5.7–6.4% (39–46 mmol/mol),
ordourdesignationdimpaired A1c (iA1c).
Other entry criteria included age $30
years ($25 years for American Indians,
Alaska Natives, Native Hawaiians, or
other Paciﬁc Islanders) and BMI 24–
42 kg/m2 (22.5–42 kg/m2 for Asians). Key
exclusion criteria included FPG, 2hPG,
or HbA1c in the diabetes range; condi-
tions affecting HbA1c, such as hemoglo-
binopathies; treatment with medications
approved for treatment of diabetes;
hyperparathyroidism; nephrolithiasis;
bariatric surgery; use of supplements
with vitamin D or calcium above study
limitations (1,000 IU/day and 600 mg/
day, respectively); regular use of tanning
beds; medications or conditions that could
interfere with absorption ormetabolism of
vitamin D; hypercalcemia; hypercalciuria;
or chronic kidney disease (estimated glo-
merular ﬁltration rate [eGFR],50mL/min
per 1.73 m2).
D2d is being conducted at 22 U.S.
collaborating clinical sites (www.d2dstudy
.org/sites). Several sites serve popula-
tions with substantial racial diversity,
while 12 sites are located at high lat-
itudes (above 37° N) to include partic-
ipants with lower ultraviolet B exposure.
D2d is an event-driven trial that will con-
tinue until the required number of diabe-
tes outcome events is reached. Results are
expected in 2019.
Screening and Baseline Assessment
Prescreening procedures were site spe-
ciﬁc and included telephone prescreen-
ings, medical chart reviews, anddat some
sitesdtargeted laboratory testing with
FPG and HbA1c. If potential participants
met prescreening criteria, they were in-
vited for in-person screening, which
occurred in two steps. At screening visit 1,
nonglycemic eligibility criteria (e.g., med-
ical history, laboratory criteria for safety)
were conﬁrmed and glycemic criteria for
prediabetes were preliminarily evaluated
by measuring FPG and HbA1c. Algorithms
using the screening visit 1 FPG and HbA1c
results guided sites as to which partic-
ipants should proceed to the next screen-
ing visit. At screening visit 2, a 75-g oral
glucose tolerance test was performed after
an 8-h overnight fast, and FPG, 2hPG, and
HbA1c were analyzed by the D2d central
laboratory to determine ﬁnal eligibility.
Screening visit 2 served as the baseline
visit for participants whowere randomized.
At screening visit 1, participants self-
reported demographics such as age, race,
ethnicity, employment, education, and
household income. Racial and ethnic cat-
egorization followed National Institutes
This article contains Supplementary Data online
at http://care.diabetesjournals.org/lookup/suppl/
doi:10.2337/dc18-0240/-/DC1.
*A complete list of the members of the D2d
Research Group can be found in the Supplemen-
tary Data.
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of Health (NIH) guidelines. Personal health
history, including smoking history, family
history of diabetes, medication use, and
use of dietary supplements, were cap-
tured by targeted questionnaires. Height
and weight were measured with a stadi-
ometer and calibrated balance beam or
electrical digital scale, respectively, follow-
ing standardized procedures.
Laboratory Methods
Specimens were processed locally. Plasma
for glucose measurement was shipped
frozen to the D2d central laboratory at
the University of Vermont’s Laboratory
for Clinical Biochemistry Research (Col-
chester, VT). Whole blood for HbA1c mea-
surement was shipped refrigerated. HbA1c
was measured using an ion-exchange
high-performance liquid chromatography
method (Tosoh G8; Tosoh Bioscience,
South San Francisco, CA). This method is
certiﬁed by NGSP (formerly the National
Glycohemoglobin Standardization Pro-
gram), and the D2d central laboratory is
certiﬁed by NGSP as a Level I Laboratory
with documented traceability to the Di-
abetes Control and Complications Trial
(DCCT) reference method (16). Plasma
glucose was measured using a hexokinase
method (Roche Glucose HK Gen.3 on the
Cobas Integra 400 or Cobas c311 analyzer;
RocheDiagnostics, Indianapolis, IN) and stan-
dardized against isotope dilution mass
spectrometry. Creatinine was measured
at each clinical site, and eGFR was calcu-
lated using the Chronic Kidney Disease
Epidemiology Collaboration equation (17).
Serum 25-hydroxyvitamin D from the
baseline and yearly visits will be analyzed
at the end of the study. Serum insulin will
also be analyzed at the end of the study
and oral glucose tolerance test–based
indices of insulin secretion and sensitivity
will be derived (3).
Statistical Analysis
Baseline characteristics are reported as
mean (SD) unless otherwise speciﬁed.
Characteristics by sex, race, and ethnicity
were compared using ANOVA tests and
x2 tests as appropriate. Two-sided P val-
ues ,0.05 were considered statistically
signiﬁcant. SAS (version 9.4; SAS Institute,
Cary, NC) was used for all analyses.
RESULTS
Recruitment
Recruitment occurred from October
2013 through December 2016. At baseline,
3,288 people met at least one of the three
ADA glycemic criteria for prediabetes and
all other nonglycemic criteria. After exclu-
sion of 865 people who met only one of
the three criteria, 2,423 participants were
randomized (Supplementary Fig. 1). Me-
dian enrollment at each site was 88 par-
ticipants (range 29–318).
Demographics Overall
Baseline characteristics are shown in
Table 1. At baseline, mean age was
59.4 years and BMI 32.0 kg/m2. Waist
circumference was 107.1 cm in men and
102.5 cm in women. A family history of
diabetes was reported by 62.5% of par-
ticipants, and 7.4% of women reported a
history of gestational diabetes mellitus.
D2d enrolled a diverse cohort: 33.3% of
participants identiﬁed as nonwhite and
9.3% identiﬁed as Hispanic or Latino. The
majority were employed at least part-
time (58.6%), approximately half (50.8%)
completed postsecondary education (i.e.,
bachelor’s degree or higher), and more
than half (53.3%) had an annual income
over $75,000. Few (6.5%) reported cur-
rent smoking. The most prevalent co-
morbidities were hypercholesterolemia
(reported by 54.5% of the cohort) and
hypertension (52.7%). In terms of sup-
plement use, 42.6% of participants were
taking vitamin D supplements (mean
730 IU/day) and 33.0% were taking cal-
cium supplements (mean 311 mg/day).
Across all participants (including those
who did not take supplements), mean
intakes were 311 IU/day for vitamin D
and 103 mg/day for calcium.
Demographics by Sex
Women comprised 44.8% of the cohort
(Table 1). Compared with men, women
were younger and had higher BMI and
lower waist circumference. Women and
men also differed in racial and ethnic
categories, employment status, education,
and annual household income. Compared
with men, women were less likely to
report a history of hypercholesterolemia,
cardiovascular disease, hypertension, sleep
apnea, and medication use for these
conditions. Women were also less likely
to report a history of smoking. Women
were more likely than men to report
a family history of diabetes (68.1 vs.
57.9%; P , 0.01) or personal history of
asthma, osteoarthritis, or osteoporosis/
osteopenia. At baseline, compared with
men, a higher proportion of women
reported taking vitamin D (48.5% for
women vs. 37.9% for men; P, 0.01) and
calcium (37.5% for women vs. 29.4% for
men; P , 0.01) supplements. Women
had lower baseline blood pressure and
higher eGFR, serum, and urine calcium
concentration.
Glycemic Proﬁle Overall
Mean baseline HbA1c was 5.9%
(41 mmol/mol), FPG 107.9 mg/dL, and
2hPG 137.2 mg/dL (Table 1). The base-
line glycemic proﬁle of the D2d cohort
covers a wide spectrum of the prediabe-
tes criteria (Table 1 and Supplementary
Fig. 2). Overall, 35.3% of participants
met all three prediabetes criteria (FPG,
2hPG, and HbA1c), 48.9% met the FPG/
HbA1c criteria only, 9.5% met the 2hPG/
FPG criteria only, and 6.3% met the
2hPG/HbA1c criteria only. Overall, 84%
of participants met both FPG and HbA1c
criteria, while 51.1% met the 2hPG cri-
terion, which has been used as an inclusion
criterion in many previous diabetes pre-
vention trials.
Glycemic Proﬁle by Sex
At baseline, mean FPG was lower among
women than men (106.9 vs. 108.8 mg/dL
respectively; P , 0.01; Table 1), while
mean 2hPG was higher in women than
men (139.7 vs. 135.3 mg/dL respectively;
P , 0.01); HbA1c concentrations did not
differ (5.9 vs. 5.9% [41 vs. 41 mmol/mol];
P = 0.23). The proportions of womenwho
met the four different combinations of
prediabetes (iA1c/IFG, IFG/IGT, IGT/iA1c
or iA1c/IFG/IGT) differed compared with
men.
Glycemic Proﬁle by Race and Ethnicity
Diabetes risk factors and glycemic proﬁle
differed by races and ethnicity (Table 2).
White participants were older than par-
ticipants of other races, while participants
of Hispanic ethnicity were younger than
non-Hispanic participants. Asian partici-
pants had lower BMI than other racial
groups, while blacks had higher baseline
BMI than whites. Waist circumference
was generally lower in Asian participants.
BMI did not differ by ethnicity, but Hispanic
men had a lower waist circumference than
non-Hispanics. White participants were less
likely to report a family history of diabetes
than black participants (59.5 vs. 68.1%, re-
spectively; P, 0.05). Fewer non-Hispanic
participants reported a family history
of diabetes compared with Hispanics
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Table 1—Demographics and clinical characteristics by sex in D2d
Overall (n = 2,423) Men (n = 1,337) Women (n = 1,086) P for men vs. women
Diabetes risk factors
Age, years, mean (SD) 59.4 (9.9) 59.9 (10.3) 58.9 (9.4) 0.01
Age range, years, n (%) ,0.01
25–44 208 (8.6) 122 (9.1) 86 (7.9)
45–59 910 (37.6) 459 (34.3) 451 (41.5)
$60 1,305 (53.9) 756 (56.5) 549 (50.6)
BMI, kg/m2, mean (SD) 32.0 (4.5) 31.5 (4.3) 32.7 (4.6) ,0.01
Waist circumference, cm, mean (SD) 105.0 (11.7) 107.1 (11.6) 102.5 (11.4) ,0.01
Self-reported family history of diabetes, n (%) 1,514 (62.5) 774 (57.9) 740 (68.1) ,0.01
Self-reported gestational diabetes mellitus, n (%) women NA NA 81 (7.4) NA
Demographics, n (%)
Race 0.04
Asian 130 (5.4) 84 (6.3) 46 (4.2)
Black or African American 616 (25.4) 318 (23.8) 298 (27.4)
White 1,616 (66.7) 902 (67.5) 714 (65.7)
Other1 61 (2.5) 33 (2.5) 28 (2.6)
Hispanic or Latino ethnicity 225 (9.3) 89 (6.7) 136 (12.5) ,0.01
Residence above 37° N latitude 1,791 (73.9) 1,022 (76.4) 769 (70.8) ,0.01
Socioeconomic, n (%)
Current employment ,0.01
Homemaker 81 (3.3) 5 (0.4) 76 (7.0)
Employed at least part-time 1,421 (58.6) 779 (58.3) 642 (59.1)
Retired 781 (32.2) 479 (35.8) 302 (27.8)
Not employed 63 (2.6) 29 (2.2) 34 (3.1)
Other 63 (2.6) 40 (3.0) 23 (2.1)
Unknown or not reported 14 (0.6) 5 (0.4) 9 (0.8)
Education ,0.01
No schooling or less than high school (no diploma or GED) 126 (5.2) 48 (3.6) 78 (7.2)
Completed high school 268 (11.1) 145 (10.8) 123 (11.3)
Some post–high school education, no certiﬁcate or
degree 420 (17.3) 236 (17.7) 184 (16.9)
Some post–high school education, Associate’s degree 379 (15.6) 201 (15.0) 178 (16.4)
Bachelor’s degree 644 (26.6) 377 (28.2) 267 (24.6)
Graduate or professional degree 574 (23.7) 324 (24.2) 250 (23.0)
Unknown or not reported 12 (0.5) 6 (0.4) 6 (0.6)
Annual household income ($) ,0.01
,35,000 374 (15.4) 184 (13.8) 190 (17.5)
36,000–50,000 352 (14.5) 175 (13.1) 177 (16.3)
51,000–75,000 405 (16.7) 199 (14.9) 206 (19.0)
75,000 or more 909 (37.5) 586 (43.8) 323 (29.7)
Unknown or not reported 383 (15.8) 193 (14.4) 190 (17.5)
Health history, n (%)
Smoking ,0.01
Never 1,410 (58.7) 711 (53.6) 699 (64.9)
Former 838 (34.9) 513 (38.7) 325 (30.2)
Current 155 (6.5) 102 (7.7) 53 (4.9)
Unknown or not reported 20 (0.8) 11 (0.8) 9 (0.8)
Medical conditions, n (%)
Hypercholesterolemia 1,321 (54.5) 807 (60.4) 514 (47.3) ,0.01
Cancer2 258 (10.6) 142 (10.6) 116 (10.7) 0.96
Cardiovascular disease3 1,360 (56.1) 802 (60.0) 558 (51.4) ,0.01
Hypertension 1,276 (52.7) 744 (55.6) 532 (49.0) ,0.01
Asthma 202 (8.3) 71 (5.3) 131 (12.1) ,0.01
Chronic obstructive pulmonary disease 34 (1.4) 18 (1.3) 16 (1.5) 0.79
Sleep apnea 299 (12.3) 203 (15.2) 96 (8.8) ,0.01
Osteoarthritis or degenerative joint disease 529 (21.8) 241 (18.0) 288 (26.5) ,0.01
Osteoporosis or osteopenia 76 (3.1) 7 (0.5) 69 (6.4) ,0.01
Medication use, n (%)
Hypercholesterolemia 1,035 (42.7) 665 (49.7) 370 (34.1) ,0.01
Hypertension 1,192 (49.2) 693 (51.8) 499 (45.9) ,0.01
Osteoporosis 13 (0.5) 1 (0.1) 12 (1.1) ,0.01
Continued on p. 1594
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(61.8 vs. 68.9%, respectively; P , 0.05).
Gestational diabetes mellitus was re-
ported more commonly among white
than black women (9.2 vs. 2.0%, re-
spectively; P, 0.05) and amongHispanic
than non-Hispanic women (16.2 vs. 6.2%,
respectively; P , 0.05). Other racial dif-
ferences were not statistically signiﬁcant.
D2d does not have data on the number of
pregnancies per woman.
Black participants had a higher mean
HbA1c concentration than other races
(6.0 vs. 5.9% [42 vs. 41 mmol/mol];
P , 0.05) despite having a lower mean
FPG (105.8 vs. 108.8 mg/dL; P , 0.05)
and a similar mean 2hPG concentration
(135.7 vs. 137.7mg/dL;P = 0.19). Glycemic
concentrations did not differ between
Hispanics vs. non-Hispanics. Compared
with white participants, a higher percent-
age of black participants met both FPG
and HbA1c criteria (52.4 for blacks vs.
47.5% for whites; P , 0.05) and 2hPG
and HbA1c criteria (14.8 vs. 7.4%; P ,
0.05), but a lower percentage met FPG
and 2hPGcriteria (2.8 vs. 7.8%;P, 0.05) or
all three criteria (30.3 vs. 37.3%; P , 0.05).
Comparison With Other Prediabetes
Trials
Glycemic eligibility criteria and the base-
line characteristics of D2d are compared
with other large diabetes prevention tri-
als in Table 3 (7–12). The trials differ in
several baseline characteristics (e.g., age,
BMI) because they targeted different
populations. D2d and the recently com-
pleted SCALE Obesity and Prediabetes
trial (SCALE), which tested liraglutide ver-
sus placebo for diabetes prevention (11),
are the only two large trials that used the
2010 ADA glycemic criteria to deﬁne a
prediabetes cohort. SCALE required that
participants meet at least one of the
three ADA glycemic criteria (compared
with D2d, which required at least two of
the three criteria). The mean baseline
2hPG concentrations in D2d and SCALE
were lower than in the older trials, which
included the 2hPG as an inclusion crite-
rion. Mean HbA1c and FPG concentrations
were comparable among all prediabetes
trials.
Comparison With Other Trials of
Vitamin D Supplementation
There are two other large trials speciﬁ-
cally designed to test the hypothesis that
vitamin D supplementation reduces the
risk of diabetes among patients at risk
for diabetes (Table 4) (18,19). D2d is
signiﬁcantly larger (2,423 participants
vs. 511 and 750) and uses a different
Table 1—Continued
Overall (n = 2,423) Men (n = 1,337) Women (n = 1,086) P for men vs. women
Dietary supplements4
Vitamin D
Participants taking vitamin D, n (%) 1,033 (42.6) 506 (37.9) 527 (48.5) ,0.01
Vitamin D intake among all participants, IU/day, mean
(SD) 311 (397) 264 (369) 369 (422) ,0.01
Vitamin D intake among participants using supplements,
IU/day, mean (SD) 730 (253) 699 (238) 761 (263) ,0.01
Calcium
Participants taking calcium, n (%) 800 (33.0) 393 (29.4) 407 (37.5) ,0.01
Calcium intake among all participants, mg/day, mean
(SD) 103 (175) 70 (126) 143 (214) ,0.01
Calcium intake among participants using supplements,
mg/day, mean (SD) 311 (166) 238 (117) 381 (177) ,0.01
Clinical testing, mean (SD)
Systolic blood pressure, mmHg 128.4 (13.4) 129.9 (12.8) 126.5 (13.9) ,0.01
Diastolic blood pressure, mmHg 77.0 (9.3) 78.7 (8.9) 74.9 (9.3) ,0.01
Serum creatinine, mg/dL 0.89 (0.19) 0.99 (0.17) 0.77 (0.14) ,0.01
eGFR5, mL/min/1.73 m2 87.1 (15.7) 85.8 (15.2) 88.6 (16.2) ,0.01
Serum calcium, mg/dL 9.41 (0.37) 9.38 (0.36) 9.44 (0.38) ,0.01
Urine calcium-to-creatinine ratio 0.09 (0.06) 0.08 (0.05) 0.09 (0.06) ,0.01
Glycemic testing, mean (SD)
FPG, mg/dL 107.9 (7.4) 108.8 (7.4) 106.9 (7.3) ,0.01
2hPG, mg/dL 137.2 (34.3) 135.3 (35.9) 139.7 (32.1) ,0.01
HbA1c, % 5.9 (0.2) 5.9 (0.2) 5.9 (0.2) 0.23
Prediabetes categories, n (%) ,0.01
iA1c + IFG 1,184 (48.9) 687 (51.4) 497 (45.8)
IFG + IGT 152 (6.3) 83 (6.2) 69 (6.4)
IGT + iA1c 231 (9.5) 103 (7.7) 128 (11.8)
iA1c + IFG + IGT 856 (35.3) 464 (34.7) 392 (36.1)
Health history and medication use were assessed by self-report. Self-reported gestational diabetes mellitus is among all women participants whether
they were pregnant or not. Racial and ethnic categories follow NIH guidelines. “Hispanic” refers to ethnicity and includes any race. IFG deﬁned
as FPG 100–125 mg/dL (5.6–6.9 mmol/L). IGT deﬁned as 2hPG glucose after a 75-g glucose load 140–199 mg/dL (7.8–11.0 mmol/L). iA1c deﬁned as
HbA1c 5.7–6.4% (39–47 mmol/mol).
1“Other” includes American Indian or Alaska Native, Native Hawaiian or other Paciﬁc Islander, or other race.
2Cancer (except for basal cell skin cancer) within 5 years of randomization was an exclusion criterion. Prostate cancer or well-differentiated thyroid
cancer not expected to require treatment over the next 4 years were not exclusions. Volunteers with history of squamous cell cancer of the
skin, which was completely excised and with no evidence of metastases, were eligible. 3Cardiovascular disease included arrhythmias, chest pain,
congestive heart failure, aortic or coronary artery disease, coronary artery bypass graft/percutaneous coronary intervention, hypertension, myocardial
infarction, palpitations, peripheral vascular disease. 4Data are derived from a direct question about medications and supplementsdnot from
a food-frequency questionnaire. 5eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.
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vitamin D dosing regimen (daily D3 vs.
weekly D3 vs. active vitamin D). The
Tromsø Study (Norway) randomized 511
white adults with prediabetes to 20,000
IU/week (;2,900 IU/day) of vitamin D3
or placebo and followed them for inci-
dent diabetes for an average of 3.3 years
(19). Risk of developing diabetes was
lower in the vitamin D versus placebo
group throughout the study, but the
difference was not statistically signiﬁcant
(hazard ratio 0.90 [95% CI 0.69–1.18]).
The Diabetes Prevention with active Vi-
tamin D (DPVD) trial has not reported
ﬁndings despite concluding in 2013 (18).
Three ongoing trials will explore the ef-
fect of vitamin D supplementation on
diabetes risk or fasting glucose and
insulin concentrations as secondary
outcomes (Table 4). Two are very large
(.20,000 participants) community-based
trials with primary outcomes of cancer,
cardiovascular disease, and mortality
(20,21); the third is an efﬁcacy trial with
primary outcomes of nonvertebral frac-
ture, functional and cognitive decline,
blood pressure, and infection (22). In
secondary analyses, D2d will assess the
effect of vitamin D supplementation on
indices of insulin secretion and insulin
sensitivity after a 75-g oral glucose tol-
erance test.
CONCLUSIONS
D2d is a large randomized clinical trial
testing the hypothesis that oral daily
vitamin D3 lowers risk of diabetes in U.S.
adults with prediabetes. The study’s large
size, with recruitment from 22 sites
across the U.S., ensures that the D2d
cohort includes people with a wide spec-
trum of diabetes risk, appropriate for
testing the underlying hypothesis, while
the placebo group will provide informa-
tion on the natural history of prediabetes
in the current era.
When designing D2d, we used contem-
porary deﬁnitions to assemble a pre-
diabetes cohort that follows the latest
guidelines, reﬂects current diagnosis pat-
terns, and identiﬁes those at the highest
risk of progression to diabetes. As such,
D2d has assembled the largest cohort of
U.S. adults with prediabetes based on the
revised ADA criteria, which include HbA1c
and lower FPG thresholds. The contem-
porary ADA criteria have been controver-
sial, as they increase the prevalence of
prediabetes by identifying people at lower
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risk for diabetes and cardiovascular com-
plications, whomay be less likely to beneﬁt
from interventions compared with people
meeting earlier criteria (13,14). D2d’s in-
clusion criteria resulted in a cohort with
lower mean 2hPG concentrations but
similar HbA1c and FPG concentrations com-
pared with previous cohorts. However,
this hyperglycemia pattern likelymatches
more closely that of contemporary pa-
tients with prediabetes, since 8 of 10 D2d
participants met both FPG and HbA1c
criteria, which are the tests most com-
monly used in clinical practice to diag-
nose prediabetes. The 2hPG criterion is
used less often in the clinical setting,
likely because of its patient and provider
burden as well as low reproducibility (23).
We currently have little knowledge of
how the 2010 ADA criteria are related to
future diabetes risk in the general U.S.
population (24,25). The control arm of
other large trials, such as the Diabetes
Prevention Program (DPP) or Acarbose
Cardiovascular Evaluation (ACE) (7,12),
cannot answer this question because
they required the 2hPG criterion, which
is rarely available in clinical practice. Re-
analyses of data from older cohorts ap-
plying the new HbA1c and FPG criteria
retrospectively are limited because these
criteria were not used to build the co-
horts (26). In addition, many trials were
conducted decades ago and changes
in the background milieu (e.g., life-
style changes, increased use of mobile
technology, slowing in the growth of
overweight and obesity) (27,28) make
previous cohorts less representative of
the current U.S. population at risk for
diabetes. Because D2d used the current
ADA criteria to identify people at risk for
diabetes and will take into consideration
all contemporary factors and inﬂuences,
the study will help establish the natural
history of prediabetes among U.S. adults
followed in a clinical trial in the contem-
porary era; such information is important
to make informed decisions about diabe-
tes risk at both the personal and public
health level. Although SCALE (liraglutide
vs. placebo), conducted in 27 countries
worldwide, also identiﬁed people with
prediabetes using the 2010 ADA criteria,
it only required that participants meet
one of three glycemic criteria for pre-
diabetes and had 50% loss to follow-up
(11), limiting the ability to interpret the
natural history of this lower-risk predia-
betes cohort.
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The D2d cohort is well balanced by sex,
which makes possible the evaluation of
vitamin D’s effect by sex given several
sex-based differences in characteristics.
Women participants are younger, use
more vitamin D and calcium supplements,
and have different health histories and
baseline clinical testing results than men.
Women also have lower FPG concentra-
tions and higher 2hPG concentrations
than men. This pattern has previously
been noted (29,30), and it is not clear
whether this is due to the same glucose
load (75 g) being given to smaller indivi-
duals or to actual sex differences in glu-
cose metabolism (31).
The D2d cohort is racially diverse,
which allows testing for effect modiﬁca-
tion by race, especially among black in-
dividuals who have both higher diabetes
risk and different vitamin D homeostasis
(32,33). In the D2d cohort, key diabetes
risk factors including age, BMI, waist
circumference, family history of diabetes,
history of gestational diabetes mellitus,
and glycemic concentrations vary be-
tween racial and ethnic groups. Notably,
black participants have a higher baseline
mean HbA1c concentration than other
races, despite having lower FPG and
similar 2hPG concentrations. This ﬁnding,
which is increasingly recognized, suggests
that HbA1c overestimates mean glycemia
in black compared with white individuals
(16). Indeed, the Department of Veterans
Affairs and Department of Defense
2017 guidelines recommend that HbA1c
6.5–6.9% (48–52 mmol/mol) alone not
be used to diagnose diabetes in the ab-
sence of a conﬁrmatory FPGmeasurement
(34). D2d will provide valuable data in this
controversial area.
Given the wide range of glycemic phe-
notypes within the current ADA deﬁni-
tion of prediabetes (e.g., iA1c, IFG, or IGT
alone or iA1c, IFG, and IGT), it is likely that
the deﬁnition of prediabetes will con-
tinue to evolve. Beyond glycemic criteria,
there are several distinct clinical pheno-
types that may be important to consider
when classifying future risk of diabetes
and diabetes-speciﬁc complications (35).
Given the large sizeof thewell-characterized
D2d cohort and long-term follow-up
with frequent (twice yearly) evaluations
of glycemic status and other clinical out-
comes (e.g., cancer, cardiovascular dis-
ease), D2d is well positioned to examine
how different phenotypes inﬂuence fu-
ture risk, including how glycemia (assessed
by FPG and 2hPG) and HbA1c are associ-
ated with future diabetes and cardiovas-
cular risk and how risk varies by age, sex,
race, and ethnicity.
Serum 25-hydroxyvitamin D values
are not currently available. Per the
study’s protocol and analytical plan,
25-hydroxyvitamin D will be analyzed
at the conclusion of the study in pairs
(before/after intervention) and in the
same analytical run to reduce systematic
error and interassay variability. We ex-
pect baseline levels to be similar between
the two groups, as factors that impact
vitamin D status (e.g., geographical loca-
tion, racial/ethnicity [36,37]) are bal-
anced between groups. Nevertheless, in
prespeciﬁed subgroup analyses, hetero-
geneity of treatment effects by baseline
25-hydroxyvitamin D levels will be as-
sessed (3).
In conclusion, in a contemporary co-
hort of U.S. adults at risk for diabetes,
D2d is expected to address two important
knowledge gaps: 1) whether vitamin D
supplementation prevents diabetes and
2) how the 2010 expanded ADA criteria
for prediabetes impact the natural his-
tory of prediabetes. The answers to these
questions will have extensive implica-
tions for the many U.S. adults at risk for
diabetes.
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